Latest Clostridium Stories
SAN DIEGO, Sept. 23, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for DIFICLIR(TM) (fidaxomicin) tablets for the treatment of adults suffering with a Clostridium difficile infection (CDI), also known as C. difficile-associated diarrhea (CDAD). (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO) DIFICLIR, which...
Severe botulism cases reported in France linked to these products SILVER SPRING, Md., Sept. 10, 2011 /PRNewswire-USNewswire/ -- The FDA is warning consumers not to eat tapenade or spreadable dried tomato paste manufactured by the French food company La Ruche. French health authorities have reported an outbreak of botulism in France linked to the company's products sold under the brand names "Les delices de Marie-Claire," "Terre de Mistral" and Les Secrets d'Anais." Eight adults are...
SAN DIEGO, Sept. 9, 2011 /PRNewswire/ -- Optimer Pharmaceuticals (NASDAQ: OPTR) today announced that 11 abstracts reporting new research findings for DIFICID(TM) (fidaxomicin) tablets will be presented at the 2011 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place September 17-20 in Chicago. DIFICID was approved by the U.S. Food and Drug Administration (FDA) in May of 2011 for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18...
MALVERN, Pa., Sept. 7, 2011 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced positive top-line results from a pilot clinical study to assess safety, tolerability, and multiple-dose pharmacokinetics of XIAFLEX® (collagenase clostridium histolyticum) in adult Dupuytren's contracture subjects with multiple palpable cords. The tolerability profile following concurrent injection of two doses of XIAFLEX into palpable cords...
Novel approach may offer treatment for other bacterial diseases Researchers at the David Geffen School of Medicine at UCLA and the University of Texas Medical Branch at Galveston have discovered a molecular process by which the body can defend against the effects of Clostridium difficile infection (CDI), pointing the way to a promising new approach for treating an intestinal disease that has become more common, more severe and harder to cure in recent years. In the U.S., several million...
A team of researchers at the Department of Energy's BioEnergy Science Center (BESC) have pinpointed the exact, single gene that controls ethanol production capacity in a microorganism. This discovery could be the missing link in developing biomass crops that produce higher concentrations of ethanol at lower costs."The Department of Energy relies on the scientific discoveries of its labs and research centers to improve the production of clean energy sources," said Energy Secretary...
MARLBOROUGH, Mass., June 27, 2011 /PRNewswire/ -- Qteros, Inc., the developer of a unique and highly efficient Consolidated Bioprocessing (CBP) platform for the lowest-cost production of cellulosic ethanol, and the University of Massachusetts Amherst, today announced two significant intellectual property (IP) advances that extend the patent estate for their unique ethanol-producing microorganism, Clostridium phytofermentans, also known as the Q Microbe®. The United States Patent and...
VOORHEES, N.J., June 16, 2011 /PRNewswire/ -- Hypervirulent strains and increased frequency of Clostridium difficile infection (CDI) have resulted in more severe disease and increased costs to the healthcare system in recent years. Fortunately, innovative therapies for the treatment of CDI are emerging. In order to improve patient outcomes, healthcare professionals must be aware of special considerations for at-risk populations, as well as the changing epidemiology, emerging novel...
FRANKFURT, Germany, June 8, 2011 /PRNewswire/ -- Merz Pharmaceuticals today announced that new data on Xeomin® (incobotulinumtoxinA), a botulinum toxin type A free from accessory (complexing) proteins, will be presented at the Movement Disorder Society's (MDS) 15th International Congress of Parkinson's Disease and Movement Disorders in Toronto, Canada. The studies found that repeated injections of XEOMIN were safe and effective in the treatment of blepharospasm and cervical dystonia (CD)...
SILVER SPRING, Md., May 27, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Dificid (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD). (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) Clostridium difficile (C. difficile) is a bacterium that can cause diarrhea and lead to colitis, other serious intestinal conditions, and death in severe cases. C. difficile bacteria are found in the stool of an infected...
Latest Clostridium Reference Libraries
Clostridium botulinum is a gram-positive, rod-shaped bacterium that produces neurotoxins, known as botulinum neurotoxins types A-G, that cause the flaccid muscular paralysis seen in botulism. It is the main paralytic agent in botox and is commonly found in soil. It is also an obligate anaerobe, meaning oxygen is poisonous to the cells. Superoxide dismutase helps C. botulinum tolerate traces of oxygen. It was first recognized and isolated in 1895 by Emile van Ermengem. Subsequent outbreaks...
